Troy Edward Wilson Acquires 100,000 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) CEO Troy Edward Wilson acquired 100,000 shares of Kura Oncology stock in a transaction that occurred on Monday, August 17th. The stock was bought at an average price of $11.12 per share, for a total transaction of $1,112,000.00. Following the completion of the acquisition, the chief executive officer owned 379,194 shares in the company, valued at $4,216,637.28. This trade represents a 35.82% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kura Oncology Trading Up 9.3%

Shares of KURA stock opened at $12.33 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. The firm has a market cap of $1.09 billion, a PE ratio of -3.66 and a beta of 0.38. The company has a 50-day moving average of $10.34 and a two-hundred day moving average of $9.39. Kura Oncology, Inc. has a 1-year low of $6.95 and a 1-year high of $12.85.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The business had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. On average, analysts predict that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on KURA shares. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a research report on Monday, June 15th. Citizens Jmp restated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday, June 15th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Finally, Wells Fargo & Company set a $24.00 target price on Kura Oncology in a report on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.62.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in KURA. IFP Advisors Inc boosted its position in Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares during the period. Allworth Financial LP increased its position in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Kura Oncology by 49.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after acquiring an additional 1,888 shares in the last quarter. Insigneo Advisory Services LLC acquired a new stake in shares of Kura Oncology in the fourth quarter valued at $105,000. Finally, LPL Financial LLC purchased a new position in Kura Oncology in the fourth quarter valued at $105,000.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.